Valle SJC, Bolaños GCE

Idioma: Español
Referencias bibliográficas: 22
Paginas: 151-156
Archivo PDF: 160.89 Kb.

RESUMEN

El síndrome cardiorenal se caracteriza por envolver alteraciones cardiacas y renales. Por su complejidad y alta mortalidad actualmente representa un reto clínico para la sociedad. Los factores que intervienen en la fisiopatología de este síndrome son multifactoriales, siendo sus principales las alteraciones hemodinámicas y activacion neurohormomal. Su diagnóstico se establece con la aparicion de falla cardíaca y falla renal de forma concomitante. Su manejo y tratamiento se basan en la optimizacion del tratamiento de falla cardíaca, y la prevención del deterioro de la funcion renal.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation. 2009;120:(16)1577-84.

2. Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367:(24)2296-304.

3. Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation. 2010;121:(23)2592- 600.

4. Brisco MA, Coca SG, Chen J, et al. Blood urea nitrogen/creatinine ratio identifies a high-risk but potentially reversible form of renal dysfunction in patients with decompensated heart failure. Circ Heart Fail. 2013;6:(2)233-9.

5. Brisco MA, Kimmel SE, Coca SG, et al. Prevalence and prognostic importance of changes in renal function after mechanical circulatory support. Circ Heart Fail. 2014;7:(1)68-75.

6. Du Y, Li X, Liu B. Advances in pathogenesis and current therapeutic strategies for cardiorenal syndrome. Life Sci. 2014;99:(1-2)1-6.

7. Elkayam U, Ng TM, Hatamizadeh P, Janmohamed M, Mehra A. Renal Vasodilatory Action of Dopamine in Patients With Heart Failure: Magnitude of Effect and Site of Action. Circulation. 2008;117:(2)200-205.

8. House AA. Cardiorenal syndrome: new developments in the understanding and pharmacologic management. Clin J Am Soc Nephrol. 2013;8:(10)1808-15.

9. Husain-Syed F, McCullough PA, Birk HW, et al. Cardio- Pulmonary-Renal Interactions: A Multidisciplinary Approach. J Am Coll Cardiol. 2015;65:(22)2433-48.

10. Kazory A. Emergence of blood urea nitrogen as a biomarker of neurohormonal activation in heart failure. Am J Cardiol. 2010;106:(5)694-700.

11. Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:(12)1319-31.

12. Mullens W, Abrahams Z, Skouri HN, et al. Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol. 2008;51:(3)300-6.

13. Nijst P, Mullens W. The acute cardiorenal syndrome: burden and mechanisms of disease. Curr Heart Fail Rep. 2014;11:(4)453-62.

14. Pollock E, Nowak A. The cardiorenal problem. Swiss Med Wkly. 2014;144:w14051.

15. Shchekochikhin D, Schrier RW, Lindenfeld J. Cardiorenal syndrome: pathophysiology and treatment. Curr Cardiol Rep. 2013;15:(7)380.

16. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:(19)1527-39.

17. Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47:(10)1987-96.

18. Testani JM, Khera AV, St John Sutton MG, et al. Effect of right ventricular function and venous congestion on cardiorenal interactions during the treatment of decompensated heart failure. Am J Cardiol. 2010;105:(4)511-6.

19. Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010;122:(3)265-72.

20. Valika AA, Costanzo MR. The acute cardiorenal syndrome type I: considerations on physiology, epidemiology, and therapy. Curr Heart Fail Rep. 2014;11:(4)382-92.

21. Waldum B, Os I. The cardiorenal syndrome: what the cardiologist needs to know. Cardiology. 2013;126:(3)175-86.

22. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:(16)1810-52.